Informations sur le produit
CC-90003 is a clinical-stage, small molecule inhibitor of the extracellular signal regulated kinase (ERK) pathway. CC-90003 binds to activated growth factor receptors and inhibits the phosphorylation of ERKs. CC-90003 has been shown to be effective in treating metastatic colorectal cancer. The drug is being developed as a processable, clinical use drug that can be administered by intravenous injection.